Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02829840
Title	Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Recruitment	Withdrawn
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	acute myeloid leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm
Therapies	Azacitidine + Ponatinib
Age Groups:	senior \| adult
Covered Countries